Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs

Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.

Material and methods. In open observational study with 24 weeks follow-up were included 60 patients with previous therapy (losartan or valsartan or telmisartan).

All patients underwent ambulatory BP monitoring, applanation tonometry (determination of the augmentation index and central BP), measurement of the pulse wave velocity, laboratory tests (lipid profile, uric acid, fasting glucose, Homeostasis Model Assessment, homocysteine, leptin, adiponectin, highly sensitive C-reactive protein, tumor necrosis factor alpha, interleukin-6).

Results. Azilsartan provided the systolic BP (29,05%, 22,5% and 8,9%) and diastolic BP reduction 18,82%, 20,46% and 8,54% (p<0,05) in patients previously treated with losartan, valsartan or telmisartan, respectively. Central systolic BP (by 25,95%, 8,78%, 11,94%), central pulse BP (by 40%, 18,38% and 19,6%), augmentation index (by 28,87%, 20,69% and 14,29%) and pulse wave velocity (by 21,57%, 24,56% and 24,92%) were decreased (p<0,05). There were positive changes in leptin, C-reactive protein, IL-6, adiponectin levels in all patients with losartan, valsartan or telmisartan initial therapy (p<0,05).

Conclusion. Azilsartan medoxomil has advantages in BP control, the arterial elasticity improving, reducing of insulin-resistance and inflammation.

1. Shlyakhto EV, Nedogoda SV, Konradi AO, et al. The concept of novel national clinical guidelines on obesity. Russ J Cardiol. 2016;4( 132):7-13. (In Russ.)

2. Fernandez-Alfonso MS, et al. Mechanisms of perivascular adipose tissue dysfunction in obesity. International Journal of Endocrinology. 2013. Article ID 402053. doi:10.1155/2013/402053.

3. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9,2:191-200. doi:10.5114/aoms.2013.33181.

4. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Russ J Cardiol. 2014;1(105):7-94. (In Russ.) doi:10.1093/euroheartj/eht151.

5. Miyata M, Ikeda Y, Nakamura S, et al. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome: the KACT-MetS Study. Circ J. 2012;76:843-51. doi:10.1253/circj.CJ-12-0153.

6. Shishido T, Konta T, Nishiyama S, et al. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Clin Exp Hypertens. 2011;33(2):117-23. doi:10.3109/10641963.2010.531837.

7. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005;28:757-8. doi:10.2337/diacare.28.3.757.

8. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-7. doi:10.1161/01.CIR.0000140265.21608.8E.

9. Kajiya T, Ho C, Wang J, et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 29:2476-83. doi: 10.1097/HJH.0b013e32834c46fd.

10. Bramlage P, Schmieder RE, Gitt AK. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. Trials. 2015;16:581. doi:10.1186/s13063-015-1100-8.

11. Bonner G, Bakris GL, Sica D. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27:479-86. doi:10.1038/jhh.2013.6

12. Sica D, White WB, Weber MA. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13:467-72. doi:10.1111/j.1751-7176.2011.00482.x.

13. . Bakris G, Sica D, Weber M. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens. 2011;13:81-88. doi:10.1111/j.1751-7176.2010.00425.x.

14. White W, Weber M, Sica D. Effects of the angiotensin receptor block azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-20. doi:10.1161/HYPERTENSIONAHA.110.163402.

15. Rakugi H, Enya K, Sugiura K. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35:552-8. doi:10.1038/hr.2012.8.

16. Ojima M, Igata H, Tanaka M. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336:801-8. doi:10.1124/jpet.110.176636.

17. Georgiopoulos G, Katsi V, Oikonomou D. Azilsartan as a potent antihypertensive drug with possible pleiotropic cardiometabolic effects: a review study. Front. Pharmacol. 2016;7:235. doi:10.3389/fphar.2016.00235.

18. Naza Mohammed Ali Mahmood, Saad Abdulrahman Hussain, Hawar Ali Ehsan Kaka Khan. Azilsartan as (add-on) treatment with methotrexate improves the disease activity of rheumatoid arthritis. BioMed Research International. 2018, аrticle ID 7164291. doi:10.1155/2018/7164291.

19. Naza Mohammed Ali Mahmood, Hussain SA, Mirza RR. Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study. Therapeutics and Clinical Risk Management. 2018;14:1379-85. doi:10.2147/TCRM.S174693.

20. Kurtz T W. Next generation multifunctional angiotensin receptor blockers. Hypertension Research. 2009;32:826-34. doi:10.1038/hr.2009.135

21. Hirabara SM, Gorjao R, Vinolo MA. Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions. J Biomed Biotechnol. 2012;379024. doi:10.1155/2012/379024.

22. Janesick A. Endocrine disrupting chemicals and the developmental programming of adipogenesis and obesity. Birth Defects Research (Part C). 2011;93:34-50. doi:10.1002/bdrc.20197.

23. Kusumoto K. Igata H, Ojima M. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur.J.Pharmacol.2011;669,84-93. doi: 10.1016/j.ejphar.2011.07.014.

24. Volpe M. New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. Integrated Blood Pressure Control. 2012;5:19-25. doi:10.2147/IBPC.S13784.